Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Modality
protein_peptide
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05476770CT.gov Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mixed Phenotype Acute Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tagraxofusp (this asset) | Therapeutic Advances in Childhood Leukemia Consortium | P1 | C · 39 |
| Daunomycin | St. Jude Children's Research Hospital | P4 | BB |
| Cytarabine | Children's Oncology Group | P4 | BB |
| Etoposide | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P3 | BB |
| Dexasone | St. Jude Children's Research Hospital | P4 | BB |
| Hydrocortisone | Children's Oncology Group | P4 | BB |
| Methotrexate | Children's Oncology Group | P4 | BB |
| Treosulfan | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P2/3 | BB |
| Calaspargase Pegol | St. Jude Children's Research Hospital | P3 | B |
+42 more in the Mixed Phenotype Acute Leukemia cohort
Other indications for Tagraxofusp
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| CD4+/CD56+ Hematodermic Neoplasm | — | P2 | BB · 70 |
| Acute Myeloid Leukemia | — | P2 | B · 56 |
| Hematopoietic And Lymphoid System Neoplasm | — | P1/2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tagraxofusp in Mixed Phenotype Acute Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tagraxofusp-mixed-phenotype-acute-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →